Neurogene
NGNE
80 hedge funds and large institutions have $119M invested in Neurogene in 2021 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 20 closing their positions.
611% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $180K
0.14% less ownership
Funds ownership: 3.05% → 2.91% (-0.14%)
4% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 26
6% less funds holding
Funds holding: 85 → 80 (-5)
25% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 20
37% less capital invested
Capital invested by funds: $187M → $119M (-$68.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$3.34M |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$664K |
| 3 |
Renaissance Technologies
New York
|
+$528K |
| 4 |
JP Morgan Chase
New York
|
+$488K |
| 5 |
Two Sigma Advisers
New York
|
+$366K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
-$10.9M |
| 2 |
Alkeon Capital Management
New York
|
-$1.68M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$906K |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$550K |
| 5 |
Swiss National Bank
Zurich,
Switzerland
|
-$534K |
NGNE Hedge Fund Activity: Q4 2021 in Review
80 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2021, worth a combined $119M — down 37% from $187M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of NGNE and 15 opened new positions — a net loss of 5 holders — while 26 trimmed existing stakes and 25 added.
The largest buyer was Millennium Management, adding an estimated $3.34M. The largest seller was Boxer Capital, exiting entirely with an estimated $10.9M sold.
- 80 institutional investors held Neurogene (NGNE) as of Q4 2021, down from 85 in Q3 2021.
- Funds reported $119M of Neurogene stock for Q4 2021, down 37% quarter-over-quarter.
- 15 funds opened new Neurogene positions in Q4 2021 and 20 closed out, a net change of -5 holders.
- The largest Neurogene buyer in Q4 2021 was Millennium Management, an estimated $3.34M added.
- The largest Neurogene seller in Q4 2021 was Boxer Capital, an estimated $10.9M sold.
Based on aggregated 13F filings for Q4 2021.